Skip to content
Screener

Ionis Pharmaceuticals IONS Revenue recognized that was included in deferred income at the beginning of the period

Revenue recognized that was included in deferred income at the beginning of the period at other companies

Diamondrock Hospitality Company logo
Diamondrock Hospitality CompanyDRH
$82K-14.6%
RBC Bearings logo
RBC BearingsRBC
$24.4M+34.8%
Allison Transmission Holdings logo
Allison Transmission HoldingsALSN
$20M+25.0%
Dine Brands Global logo
Dine Brands GlobalDIN
$1.9M-29.6%
Teradata logo
TeradataTDC
$138M-20.2%
GigaCloud Technology logo
GigaCloud TechnologyGCT
$5.89M+4.0%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.

The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:25 PM EST
Fiscal year
FY2026
Accession
0000874015-26-000115

We are often entitled to bill our customers and receive payment from our customers in advance of our obligation to provide services or transfer goods to our partners. In these instances, we include the amounts in deferred revenue in our consolidated balance sheets. During the years ended December 31, 2025 and 2024, we recognized $78.4 million and $166.1 million of revenue from amounts that were in our beginning deferred revenue balance for each respective period. For further discussion, refer to our revenue recognition policy above.

Item 15. Exhibits and Financial Statement Schedules

FAQ

What is Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period?
Ionis Pharmaceuticals (IONS) reported revenue recognized that was included in deferred income at the beginning of the period of $19.6M in Q4 2025.
How has Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period changed year-over-year?
Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period decreased by 52.8% year-over-year, from $41.53M to $19.6M.
What does revenue recognized that was included in deferred income at the beginning of the period mean?
Reflects the portion of deferred revenue or contract liabilities that has been converted into recognized revenue during the reporting period. This occurs when performance obligations under a contract are satisfied, such as achieving clinical milestones or delivering licensed technology.

Ask your AI about Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude